1. Fundación Arturo López Pérez, Providencia, Santiago, Chile;
2. Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia;
3. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea;
4. Institut Claudius Regaud, Toulouse, France;
5. Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain;
6. Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile;
7. Institut de Cancérologie de l’Ouest, Centre René Gauducheau ICO, Saint-Herblain, France;
8. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada;
9. Department of Medical Oncology (Hospital Clinic)/Translational Genomics and Targeted Therapies in Solid Tumors (IDIBAPs), Barcelona, Spain;
10. Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA;
11. Rambam Health Care Campus, Division of Oncology, Haifa, Israel;
12. The Alfred Hospital, Melbourne, VIC, Australia;
13. Asan Medical Center, Seoul, South Korea;
14. University Hospital Regensburg, Regensburg, Germany;
15. Centre Oscar Lambret, Lille, France;
16. Merck & Co., Inc., Kenilworth, NJ;
17. Eisai Inc., Woodcliff Lake, NJ;
18. The Christie NHS Foundation Trust, Manchester, United Kingdom;